A woman in Ottawa-Quebec developed the first blood clot in Canada after being vaccinated with the Oxford-AstraZeneca vaccine.
The news was released when Health Canada said it was investigating reports of blood clots associated with the Johnson & Johnson vaccine in the United States.
The Quebec Department of Health and the Public Health Agency of Canada reported on Tuesday an event related to the Oxford-AstraZeneca vaccine.
Quebec states that female patients of unknown age are receiving proper care and recovering at home.
The woman received a vaccine manufactured at the Serum Institute of India, known as Cobishield.
Health Canada has asked AstraZeneca for a complete risk assessment of the vaccine after a similar clot was reported in Europe, but side effects are very rare and the benefits of the vaccine still outweigh the risks. It states.
With over 700,000 vaccines given in Canada, the risk of blood clots from COVID-19 itself is much higher than with the vaccine.
The United States today suspended the use of the Johnson & Johnson vaccine following reports of six similar blood clots. Health Canada said it also asked the drug company for more information on the vaccine.
Health Canada approved AstraZeneca on February 26th and J & J on March 5th, but so far only AstraZeneca has been used.
About 2 million shipments have been shipped.
J & J dosages are not provided and are not planned for the next few weeks.